Association of Autoimmune Disorders and Disease-modifying
Antirheumatic Drugs: (DMARDs) with the Risk of Alzheimer’s and/or
Dementia: A Population Study Using Medicare Beneficiary Data

Qian      Ding; Jennifer      Lamberts; Alison   M.   Konieczny; Tyler   B.   Bringedahl; Kiara   Y.   Torres Garcia

doi:10.2174/0115672050289966240110041616

Abstract

Objectives: Alzheimer’s disease (AD) and/or dementia is a prevalent neurocognitive disorder primarily affecting individuals over the age of 65. Identifying specific causes of AD and/or dementia can be challenging, with emerging evidence suggesting a potential association with autoimmune inflammatory conditions such as rheumatoid arthritis (RA). This study aimed to assess the prevalence rate of AD and/or dementia among Medicare beneficiaries reporting an autoimmune disorder. Additionally, this study sought to identify the comparative prevalence of AD and/or dementia in patients with an autoimmune disorder who were using disease-modifying antirheumatic drugs (DMARDs) compared to those not using DMARDs.

Methods: Cross-sectional secondary data analyses were conducted on Medicare Current Beneficiary Survey (MCBS) data from 2017 and 2018. The MCBS data consists of a nationally representative sample of the Medicare population, a population that is largely 65 and older, and provides de-identified patient information. Patients from this dataset with a self-reported autoimmune disorder were included in the analyses. Descriptive analyses were conducted on demographic variables, chronic conditions, and medication use. The prevalence of AD and/or dementia was compared between patients with and without an autoimmune disorder. A backward stepwise selection regression was used to identify the risk factors associated with the prevalence of AD and/or dementia.

Results: The study included 18,929 Medicare beneficiaries, with 4,405 identified as having one autoimmune disorder. The prevalence of AD and/or dementia was significantly higher in patients with an autoimmune disorder. The multivariate regression showed that RA was significantly associated with a higher risk of AD and/or dementia. Other demographic factors, including advanced age, African-American or Hispanic ethnicity, low body mass index, and chronic conditions of ischemic heart disease, history of myocardial infarction, history of stroke, depression, mental health disorder(s), and traumatic brain injury also showed statistically significant associations with AD and/or dementia. Patients using DMARDs demonstrated a reduced likelihood of having AD and/or dementia, compared to patients not using DMARDs.

Conclusion: This study provides evidence of an association between RA and increased risk of AD and/or dementia. The findings suggest that DMARD use may have a protective effect against the development of AD and/or dementia in patients with an autoimmune disorder.

« Previous

[1]
Huang, J. Dementia. In: Merck Manual Professional Version; Merck Sharp & Dohme Corp: Kenilworth, NJ, 2021. 

[2]
Huang, J. Dementia.Merck Manual Consumer Version; Merck Sharp & Dohme Corp: Kenilworth, NJ, 2021. 

[3]
Gale, S.A.; Acar, D.; Daffner, K.R. Dementia. Am. J. Med.,  2018, 131(10), 1161-1169.
 [http://dx.doi.org/10.1016/j.amjmed.2018.01.022] [PMID: 29425707]

[4]
Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement.,  2021, 17(3), 327-406.
 [http://dx.doi.org/10.1002/alz.12328] [PMID: 33756057]

[5]
Nichols, E.; Szoeke, C.E.I.; Vollset, S.E.; Abbasi, N.; Abd-Allah, F.; Abdela, J.; Aichour, M.T.E.; Akinyemi, R.O.; Alahdab, F.; Asgedom, S.W.; Awasthi, A.; Barker-Collo, S.L.; Baune, B.T.; Béjot, Y.; Belachew, A.B.; Bennett, D.A.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Brayne, C.; Carpenter, D.O.; Carvalho, F.; Catalá-López, F.; Cerin, E.; Choi, J-Y.J.; Dang, A.K.; Degefa, M.G.; Djalalinia, S.; Dubey, M.; Duken, E.E.; Edvardsson, D.; Endres, M.; Eskandarieh, S.; Faro, A.; Farzadfar, F.; Fereshtehnejad, S-M.; Fernandes, E.; Filip, I.; Fischer, F.; Gebre, A.K.; Geremew, D.; Ghasemi-Kasman, M.; Gnedovskaya, E.V.; Gupta, R.; Hachinski, V.; Hagos, T.B.; Hamidi, S.; Hankey, G.J.; Haro, J.M.; Hay, S.I.; Irvani, S.S.N.; Jha, R.P.; Jonas, J.B.; Kalani, R.; Karch, A.; Kasaeian, A.; Khader, Y.S.; Khalil, I.A.; Khan, E.A.; Khanna, T.; Khoja, T.A.M.; Khubchandani, J.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Koyanagi, A.; Krohn, K.J.; Logroscino, G.; Lorkowski, S.; Majdan, M.; Malekzadeh, R.; März, W.; Massano, J.; Mengistu, G.; Meretoja, A.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mokdad, A.H.; Mondello, S.; Moradi, G.; Nagel, G.; Naghavi, M.; Naik, G.; Nguyen, L.H.; Nguyen, T.H.; Nirayo, Y.L.; Nixon, M.R.; Ofori-Asenso, R.; Ogbo, F.A.; Olagunju, A.T.; Owolabi, M.O.; Panda-Jonas, S.; Passos, V.M.A.; Pereira, D.M.; Pinilla-Monsalve, G.D.; Piradov, M.A.; Pond, C.D.; Poustchi, H.; Qorbani, M.; Radfar, A.; Reiner, R.C., Jr; Robinson, S.R.; Roshandel, G.; Rostami, A.; Russ, T.C.; Sachdev, P.S.; Safari, H.; Safiri, S.; Sahathevan, R.; Salimi, Y.; Satpathy, M.; Sawhney, M.; Saylan, M.; Sepanlou, S.G.; Shafieesabet, A.; Shaikh, M.A.; Sahraian, M.A.; Shigematsu, M.; Shiri, R.; Shiue, I.; Silva, J.P.; Smith, M.; Sobhani, S.; Stein, D.J.; Tabarés-Seisdedos, R.; Tovani-Palone, M.R.; Tran, B.X.; Tran, T.T.; Tsegay, A.T.; Ullah, I.; Venketasubramanian, N.; Vlassov, V.; Wang, Y-P.; Weiss, J.; Westerman, R.; Wijeratne, T.; Wyper, G.M.A.; Yano, Y.; Yimer, E.M.; Yonemoto, N.; Yousefifard, M.; Zaidi, Z.; Zare, Z.; Vos, T.; Feigin, V.L.; Murray, C.J.L. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global burden of disease study 2016. Lancet Neurol.,  2019, 18(1), 88-106.
 [http://dx.doi.org/10.1016/S1474-4422(18)30403-4] [PMID: 30497964]

[6]
Rajan, KB; Weuve, J; Barnes, LL; McAninch, EA; Wilson, RS; Evans, DA Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement,  2021, 17(12), 1966-1975.

[7]
Ahmad, F.B.; Anderson, R.N. The leading causes of death in the US for 2020. JAMA,  2021, 325(18), 1829-1830.
 [http://dx.doi.org/10.1001/jama.2021.5469] [PMID: 33787821]

[8]
Burns, A.; Iliffe, S. Alzheimer’s disease. BMJ,  2009, 338(Feb 05), b158.
 [http://dx.doi.org/10.1136/bmj.b158] [PMID: 19196745]

[9]
Atri, A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med. Clin. North Am.,  2019, 103(2), 263-293.
 [http://dx.doi.org/10.1016/j.mcna.2018.10.009] [PMID: 30704681]

[10]
Jang, H.D.; Park, J.S.; Kim, D.W.; Han, K.; Shin, B.J.; Lee, J.C.; Choi, S.W.; Suh, S.W.; Yang, J.H.; Park, S.Y.; Cho, W.J.; Hong, J.Y. Relationship between dementia and ankylosing spondylitis: A nationwide, population-based, retrospective longitudinal cohort study. PLoS One,  2019, 14(1), e0210335.
 [http://dx.doi.org/10.1371/journal.pone.0210335] [PMID: 30703142]

[11]
Lin, C.C.; Lin, H.C.; Chiu, H.W. Association between psoriasis and dementia: A population-based case-control study. Am. J. Clin. Dermatol.,  2019, 20(3), 457-463.
 [http://dx.doi.org/10.1007/s40257-018-00420-8] [PMID: 30649680]

[12]
Ungprasert, P.; Wijarnpreecha, K.; Thongprayoon, C. Rheumatoid arthritis and the risk of dementia: A systematic review and meta-analysis. Neurol. India,  2016, 64(1), 56-61.
 [http://dx.doi.org/10.4103/0028-3886.173623] [PMID: 26754993]

[13]
Huang, KL; Yeh, CC; Wu, SI; Huang, KY; Yang, YH; Kuo, TY Risk of dementia among individuals with psoriasis: A nationwide population-based cohort study in Taiwan. J. Clin. Psychiatr.,  2019, 80(3), 18m12462.

[14]
Zingel, R.; Bohlken, J.; Kostev, K. Association between inflammatory bowel disease and dementia: A retrospective cohort study. J. Alzheimers Dis.,  2021, 80(4), 1471-1478.
 [http://dx.doi.org/10.3233/JAD-210103] [PMID: 33720902]

[15]
Lin, Y.R.; Chou, L.C.; Chen, H.C.; Liou, T.H.; Huang, S.W.; Lin, H.W. Increased risk of dementia in patients with systemic lupus erythematosus: A nationwide population-based cohort study. Arthritis Care Res.,  2016, 68(12), 1774-1779.
 [http://dx.doi.org/10.1002/acr.22914] [PMID: 27111329]

[16]
Charoenngam, N.; Rittiphairoj, T.; Ponvilawan, B.; Ungprasert, P. Patients with psoriasis have a higher risk of dementia: A systematic review and meta-analysis. Indian J. Dermatol. Venereol. Leprol.,  2021, 87(3), 364-370.
 [http://dx.doi.org/10.25259/IJDVL_732_19] [PMID: 33666046]

[17]
Wang, Y.C.; Lin, M.S.; Huang, A.P.H.; Wu, C.C.; Kung, W.M. Association between systemic rheumatic diseases and dementia risk: A meta-analysis. Front. Immunol.,  2022, 13, 1054246.
 [http://dx.doi.org/10.3389/fimmu.2022.1054246] [PMID: 36439141]

[18]
Kodishala, C.; Hulshizer, C.A.; Kronzer, V.L.; Davis, J.M., III; Ramanan, V.K.; Vassilaki, M.; Mielke, M.M.; Crowson, C.S.; Myasoedova, E. Risk factors for dementia in patients with incident rheumatoid arthritis: A population-based cohort study. J. Rheumatol.,  2023, 50(1), 48-55.
 [http://dx.doi.org/10.3899/jrheum.220200] [PMID: 35840149]

[19]
Chen, K.T.; Chen, Y.C.; Fan, Y.H.; Lin, W.X.; Lin, W.C.; Wang, Y.H.; Lin, L.; Chiou, J.Y.; Wei, J.C.C. Rheumatic diseases are associated with a higher risk of dementia: A nation-wide, population-based, case-control study. Int. J. Rheum. Dis.,  2018, 21(2), 373-380.
 [http://dx.doi.org/10.1111/1756-185X.13246] [PMID: 29243407]

[20]
Gendelman, O.; Tiosano, S.; Shoenfeld, Y.; Comaneshter, D.; Amital, H.; Cohen, A.D.; Amital, D. High proportions of dementia among SLE patients: A big data analysis. Int. J. Geriatr. Psychiatry,  2018, 33(3), 531-536.
 [http://dx.doi.org/10.1002/gps.4819] [PMID: 29114974]

[21]
Lin, T.M.; Chen, W.S.; Sheu, J.J.; Chen, Y.H.; Chen, J.H.; Chang, C.C. Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study. PLoS One,  2018, 13(1), e0186475.
 [http://dx.doi.org/10.1371/journal.pone.0186475] [PMID: 29304089]

[22]
Rønnow Sand, J.; Troelsen, F.S.; Horváth-Puhó, E.; Henderson, V.W.; Sørensen, H.T.; Erichsen, R. Risk of dementia in patients with inflammatory bowel disease: A Danish population-based study. Aliment. Pharmacol. Ther.,  2022, 56(5), 831-843.
 [http://dx.doi.org/10.1111/apt.17119] [PMID: 35781292]

[23]
Wallin, K.; Solomon, A.; Kåreholt, I.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: A population-based study. J. Alzheimers Dis.,  2012, 31(3), 669-676.
 [http://dx.doi.org/10.3233/JAD-2012-111736] [PMID: 22647255]

[24]
Wotton, C.J.; Goldacre, M.J. Associations between specific autoimmune diseases and subsequent dementia: Retrospective record-linkage cohort study, UK. J. Epidemiol. Community Health,  2017, 71(6), 576-583.
 [http://dx.doi.org/10.1136/jech-2016-207809] [PMID: 28249989]

[25]
Yuan, S; Dan, L; Zhang, Y; Wu, J; Zhao, J; Kivipelto, M Digestive system diseases, genetic risk, and incident dementia: A prospective cohort study. Am. J. Prev. Med.,  2023, S0749-3797(23)00433–6.
 [http://dx.doi.org/10.1016/j.amepre.2023.10.017]

[26]
Zhang, B.; Wang, H.E.; Bai, Y.M.; Tsai, S.J.; Su, T.P.; Chen, T.J.; Wang, Y.P.; Chen, M.H. Inflammatory bowel disease is associated with higher dementia risk: A nationwide longitudinal study. Gut,  2021, 70(1), 85-91.
 [http://dx.doi.org/10.1136/gutjnl-2020-320789] [PMID: 32576641]

[27]
Zhao, Z.; Rocha, N.P.; Salem, H.; Diniz, B.S.; Teixeira, A.L. The association between systemic lupus erythematosus and dementia A meta-analysis. Dement. Neuropsychol.,  2018, 12(2), 143-151.
 [http://dx.doi.org/10.1590/1980-57642018dn12-020006] [PMID: 29988333]

[28]
Zhou, M.; Xu, R.; Kaelber, D.C.; Gurney, M.E. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS One,  2020, 15(3), e0229819.
 [http://dx.doi.org/10.1371/journal.pone.0229819] [PMID: 32203525]

[29]
Chou, R.C.; Kane, M.; Ghimire, S.; Gautam, S.; Gui, J. Treatment for rheumatoid arthritis and risk of alzheimer’s disease: A nested case-control analysis. CNS Drugs,  2016, 30(11), 1111-1120.
 [http://dx.doi.org/10.1007/s40263-016-0374-z] [PMID: 27470609]

[30]
Ponvilawan, B.; Charoenngam, N.; Rittiphairoj, T.; Ungprasert, P. Ankylosing spondylitis is associated with an increased risk of dementia: A systematic review and meta-analysis. Int. J. Rheum. Dis.,  2020, 23(11), 1452-1459.
 [http://dx.doi.org/10.1111/1756-185X.13920] [PMID: 32715652]

[31]
Kim, M.; Park, H.E.; Lee, S.H.; Han, K.; Lee, J.H. Increased risk of Alzheimer’s disease in patients with psoriasis: A nationwide population-based cohort study. Sci. Rep.,  2020, 10(1), 6454.
 [http://dx.doi.org/10.1038/s41598-020-63550-2] [PMID: 32296117]

[32]
Simmons, C.R.; Zou, F.; Younkin, S.G.; Estus, S. Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer’s disease. Mol. Neurodegener.,  2011, 6(1), 33.
 [http://dx.doi.org/10.1186/1750-1326-6-33] [PMID: 21595938]

[33]
Aggarwal, M.; Alkhayyat, M.; Abou Saleh, M.; Sarmini, M.T.; Singh, A.; Garg, R.; Garg, P.; Mansoor, E.; Padival, R.; Cohen, B.L. Alzheimer disease occurs more frequently in patients with inflammatory bowel disease: Insight from a nationwide study. J. Clin. Gastroenterol.,  2023, 57(5), 501-507.
 [http://dx.doi.org/10.1097/MCG.0000000000001714] [PMID: 35470286]

[34]
Szandruk-Bender, M.; Wiatrak, B.; Szeląg, A. The risk of developing Alzheimer’s disease and Parkinson’s disease in patients with inflammatory bowel disease: A meta-analysis. J. Clin. Med.,  2022, 11(13), 3704.
 [http://dx.doi.org/10.3390/jcm11133704] [PMID: 35806985]

[35]
Watad, A.; McGonagle, D.; Anis, S.; Carmeli, R.; Cohen, A.D.; Tsur, A.M.; Ben-Shabat, N.; Luigi Bragazzi, N.; Lidar, M.; Amital, H. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacol. Res.,  2022, 182, 106325.
 [http://dx.doi.org/10.1016/j.phrs.2022.106325] [PMID: 35752359]

[36]
Sangha, P.S.; Thakur, M.; Akhtar, Z.; Ramani, S.; Gyamfi, R.S. The link between rheumatoid arthritis and dementia: A review. Cureus,  2020, 12(4), e7855.
 [http://dx.doi.org/10.7759/cureus.7855] [PMID: 32489719]

[37]
Newby, D.; Prieto-Alhambra, D.; Duarte-Salles, T.; Ansell, D.; Pedersen, L.; van der Lei, J.; Mosseveld, M.; Rijnbeek, P.; James, G.; Alexander, M.; Egger, P.; Podhorna, J.; Stewart, R.; Perera, G.; Avillach, P.; Grosdidier, S.; Lovestone, S.; Nevado-Holgado, A.J. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimers Res. Ther.,  2020, 12(1), 38.
 [http://dx.doi.org/10.1186/s13195-020-00606-5] [PMID: 32252806]

[38]
Huang, L.C.; Chang, Y.H.; Yang, Y.H. Can disease-modifying anti-rheumatic drugs reduce the risk of developing dementia in patients with rheumatoid arthritis? Neurotherapeutics,  2019, 16(3), 703-709.
 [http://dx.doi.org/10.1007/s13311-019-00715-6] [PMID: 30945124]

[39]
Judge, A.; Garriga, C.; Arden, N.K.; Lovestone, S.; Prieto-Alhambra, D.; Cooper, C.; Edwards, C.J. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement.,  2017, 3(4), 612-621.
 [http://dx.doi.org/10.1016/j.trci.2017.10.002] [PMID: 29201995]

[40]
Sattui, S.E.; Navarro-Millan, I.; Xie, F.; Rajan, M.; Yun, H.; Curtis, J.R. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs – Analysis of a national claims database. Semin. Arthritis Rheum.,  2022, 57, 152083.
 [http://dx.doi.org/10.1016/j.semarthrit.2022.152083] [PMID: 36155968]

[41]
Zheng, C.; Fillmore, N.R.; Ramos-Cejudo, J.; Brophy, M.; Osorio, R.; Gurney, M.E.; Qiu, W.Q.; Au, R.; Perry, G.; Dubreuil, M.; Chen, S.G.; Qi, X.; Davis, P.B.; Do, N.; Xu, R. Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimers Dement.,  2022, 18(6), 1248-1259.
 [http://dx.doi.org/10.1002/alz.12465] [PMID: 34569707]

[42]
Cooper, J.; Pastorello, Y.; Slevin, M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front. Immunol.,  2023, 14, 1087571.
 [http://dx.doi.org/10.3389/fimmu.2023.1087571] [PMID: 36776896]

[43]
Yeung, C.H.C.; Au Yeung, S.L.; Schooling, C.M. Association of autoimmune diseases with Alzheimer’s disease: A mendelian randomization study. J. Psychiatr. Res.,  2022, 155, 550-558.
 [http://dx.doi.org/10.1016/j.jpsychires.2022.09.052] [PMID: 36198219]

[44]
Kridin, K.; Linder, D.; Shalom, G.; Piaserico, S.; Babaev, M.; Freud, T.; Comaneshter, D.; Cohen, A. Psoriasis and dementia: A cross-sectional study of 121,801 patients. Acta Derm. Venereol.,  2020, 100(15), adv00250.
 [http://dx.doi.org/10.2340/00015555-3595] [PMID: 32725254]

[45]
Cai, Q.; Xin, Z.; Zuo, L.; Li, F.; Liu, B. Alzheimer’s disease and rheumatoid arthritis: A Mendelian randomization study. Front. Neurosci.,  2018, 12, 627.
 [http://dx.doi.org/10.3389/fnins.2018.00627] [PMID: 30258348]

[46]
Min, C.; Bang, W.J.; Kim, M.; Oh, D.J.; Choi, H.G. Rheumatoid arthritis and neurodegenerative dementia: A nested case-control study and a follow-up study using a national sample cohort. Clin. Rheumatol.,  2020, 39(1), 159-166.
 [http://dx.doi.org/10.1007/s10067-019-04769-x] [PMID: 31523786]

[47]
Wu, C.Y.; Hu, H.Y.; Chou, Y.J.; Li, C.P.; Chang, Y.T. Psoriasis is not a risk factor for dementia: A 12-year nationwide population-based cohort study. Arch. Dermatol. Res.,  2020, 312(9), 657-664.
 [http://dx.doi.org/10.1007/s00403-020-02057-2] [PMID: 32152723]

[48]
Bae, S.C.; Lee, Y.H. Causal association between rheumatoid arthritis and a decreased risk of Alzheimer’s disease. Z. Rheumatol.,  2019, 78(4), 359-364.
 [http://dx.doi.org/10.1007/s00393-018-0504-8] [PMID: 29974225]

[49]
Kao, L.T.; Kang, J.H.; Lin, H.C.; Huang, C.C.; Lee, H.C.; Chung, S.D. Rheumatoid arthritis was negatively associated with Alzheimer’s disease: A population-based case-control study. PLoS One,  2016, 11(12), e0168106.
 [http://dx.doi.org/10.1371/journal.pone.0168106] [PMID: 27997574]

[50]
Policicchio, S.; Ahmad, A.N.; Powell, J.F.; Proitsi, P. Rheumatoid arthritis and risk for Alzheimer’s disease: A systematic review and meta-analysis and a Mendelian Randomization study. Sci. Rep.,  2017, 7(1), 12861.
 [http://dx.doi.org/10.1038/s41598-017-13168-8] [PMID: 28993680]

[51]
Cheng, C-Y. Psoriasis is not associated with the risk of dementia: A population-based cohort study. J. Am. Acad. Dermatol., 2020.
 [PMID: 32891780]

[52]
Chou, M.H.; Wang, J.Y.; Lin, C.L.; Chung, W.S. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case–control study. Toxicol. Appl. Pharmacol.,  2017, 334, 217-222.
 [http://dx.doi.org/10.1016/j.taap.2017.09.014] [PMID: 28927738]

[53]
Desai, R.J.; Varma, V.R.; Gerhard, T.; Segal, J.; Mahesri, M.; Chin, K.; Horton, D.B.; Kim, S.C.; Schneeweiss, S.; Thambisetty, M. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw. Open,  2022, 5(4), e226567.
 [http://dx.doi.org/10.1001/jamanetworkopen.2022.6567] [PMID: 35394510]

[54]
Andrews, S.J.; Goate, A. Mendelian randomization indicates that TNF is not causally associated with Alzheimer’s disease. Neurobiol. Aging,  2019, 84, 241.e1-241.e3.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2019.09.003] [PMID: 31587925]

[55]
Booth, M.J.; Kobayashi, L.C.; Janevic, M.R.; Clauw, D.; Piette, J.D. No increased risk of Alzheimer’s disease among people with immune-mediated inflammatory diseases: Findings from a longitudinal cohort study of U.S. older adults. BMC Rheumatol.,  2021, 5(1), 48.
 [http://dx.doi.org/10.1186/s41927-021-00219-x] [PMID: 34763722]

[56]
Lu, K.; Wang, H.K.; Yeh, C.C.; Huang, C.Y.; Sung, P.S.; Wang, L.C.; Muo, C.H.; Sung, F.C.; Chen, H.J.; Li, Y.C.; Chang, L.C.; Tsai, K.J. Association between autoimmune rheumatic diseases and the risk of dementia. BioMed Res. Int.,  2014, 2014, 1-7.
 [http://dx.doi.org/10.1155/2014/861812] [PMID: 24877143]

[57]
Medicare Current Beneficiary Survey (MCBS)  Available from: https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey

[58]
Adler, G.S. A profile of the medicare current beneficiary survey. Health Care Financ. Rev.,  1994, 15(4), 153-163.
 [PMID: 10138483]

[59]
National Institutes of Health, Office of Human Subjects Research Protection. Types of research: human subjects research vs. not human subjects research. NIH investigator manual for human subjects research; U.S. Department of Health and Human Services, National Institutes of Health, 2022. 

[60]

Medicare Current Beneficiary Survey Methodology Report; Centers for Medicare & Medicaid Services, 2017. 

[61]

Medicare Current Beneficiary Survey Methodology Report; Centers for Medicare & Medicaid Services, 2018. 

[62]
Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med.,  2007, 4(10), e297.
 [http://dx.doi.org/10.1371/journal.pmed.0040297] [PMID: 17941715]

[63]
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies: STROBE Checklist: cohort, case-control, and cross-sectional studies (combined). 2023. Available from: https://www.strobe-statement.org/download/strobe-checklist-wide-cohort-case-control-and-cross-sectional-studies-combined-doc

[64]
Kronzer, V.L.; Crowson, C.S.; Davis, J.M., III; Vassilaki, M.; Mielke, M.M.; Myasoedova, E. Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. Semin. Arthritis Rheum.,  2021, 51(4), 853-857.
 [http://dx.doi.org/10.1016/j.semarthrit.2021.06.003] [PMID: 34174733]

[65]
Li, X.; Sundquist, J.; Zöller, B.; Sundquist, K. Dementia and Alzheimer’s disease risks in patients with autoimmune disorders. Geriatr. Gerontol. Int.,  2018, 18(9), 1350-1355.
 [http://dx.doi.org/10.1111/ggi.13488] [PMID: 30044040]

[66]
Li, P.; Zheng, Y.; Chen, X. Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics. Front. Pharmacol.,  2017, 8, 460.
 [http://dx.doi.org/10.3389/fphar.2017.00460] [PMID: 28785220]

[67]
Tarkowski, E.; Andreasen, N.; Tarkowski, A.; Blennow, K. Intrathecal inflammation precedes development of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry,  2003, 74(9), 1200-1205.
 [http://dx.doi.org/10.1136/jnnp.74.9.1200] [PMID: 12933918]

[68]
Vadasz, Z.; Haj, T.; Kessel, A.; Toubi, E. Age-related autoimmunity. BMC Med.,  2013, 11(1), 94.
 [http://dx.doi.org/10.1186/1741-7015-11-94] [PMID: 23556986]

[69]
Rajan, K.B.; Weuve, J.; Barnes, L.L.; Wilson, R.S.; Evans, D.A. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement.,  2019, 15(1), 1-7.
 [http://dx.doi.org/10.1016/j.jalz.2018.07.216] [PMID: 30195482]

[70]
Gillis, C.; Montenigro, P.; Nejati, M.; Maserejian, N. Estimating prevalence of early Alzheimer’s disease in the United States, accounting for racial and ethnic diversity. Alzheimers Dement.,  2023, 19(5), 1841-1848.
 [http://dx.doi.org/10.1002/alz.12822] [PMID: 36322470]

[71]
Singh-Manoux, A.; Dugravot, A.; Shipley, M.; Brunner, E.J.; Elbaz, A.; Sabia, S.; Kivimaki, M. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimers Dement.,  2018, 14(2), 178-186.
 [http://dx.doi.org/10.1016/j.jalz.2017.06.2637] [PMID: 28943197]

[72]
Pegueroles, J.; Jiménez, A.; Vilaplana, E.; Montal, V.; Carmona-Iragui, M.; Pané, A.; Alcolea, D.; Videla, L.; Casajoana, A.; Clarimón, J.; Ortega, E.; Vidal, J.; Blesa, R.; Lleó, A.; Fortea, J. Obesity and Alzheimer’s disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget,  2018, 9(78), 34691-34698.
 [http://dx.doi.org/10.18632/oncotarget.26162] [PMID: 30410669]

[73]
Li, J.; Liu, C.; Ang, T.F.A.; Au, R. BMI decline patterns and relation to dementia risk across four decades of follow-up in the Framingham Study. Alzheimers Dement.,  2023, 19(6), 2520-2527.
 [http://dx.doi.org/10.1002/alz.12839] [PMID: 36519667]

[74]
Fitzpatrick, A.L.; Kuller, L.H.; Lopez, O.L.; Diehr, P.; O’Meara, E.S.; Longstreth, W.T., Jr; Luchsinger, J.A. Midlife and late-life obesity and the risk of dementia: Cardiovascular health study. Arch. Neurol.,  2009, 66(3), 336-342.
 [http://dx.doi.org/10.1001/archneurol.2008.582] [PMID: 19273752]

[75]
Malone, D.C.; McLaughlin, T.P.; Wahl, P.M.; Leibman, C.; Arrighi, H.M.; Cziraky, M.J.; Mucha, L.M. Burden of Alzheimer’s disease and association with negative health outcomes. Am. J. Manag. Care,  2009, 15(8), 481-488.
 [PMID: 19670951]

[76]
Widdifield, J.; Paterson, J.M.; Bernatsky, S.; Tu, K.; Thorne, J.C.; Ahluwalia, V.; Ivers, N.; Butt, D.; Jaakkimainen, R.L.; Tomlinson, G.; Bombardier, C. The rising burden of rheumatoid arthritis surpasses rheumatology supply in Ontario. Can. J. Public Health,  2013, 104(7), e450-e455.
 [http://dx.doi.org/10.17269/cjph.104.4115] [PMID: 24495819]

[77]
Widdifield, J.; Bombardier, C.; Bernatsky, S.; Paterson, J.M.; Green, D.; Young, J.; Ivers, N.; Butt, D.A.; Jaakkimainen, R.L.; Thorne, J.C.; Tu, K. An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: The influence of the reference standard on algorithm performance. BMC Musculoskelet. Disord.,  2014, 15(1), 216.
 [http://dx.doi.org/10.1186/1471-2474-15-216] [PMID: 24956925]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115672050289966240110041616	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828

Current Alzheimer Research

Association of Autoimmune Disorders and Disease-modifying Antirheumatic Drugs: (DMARDs) with the Risk of Alzheimer’s and/or Dementia: A Population Study Using Medicare Beneficiary Data

Abstract Play Pause

Related Journals

Related Books

Abstract